BWXT Medical Sale Includes Ongoing Partnership Structure
Dow Jones08-04 05:33
BWXT's sale of its medical business to Nordic Capital isn't a clean break. The company will retain a meaningful minority ownership stake in the divested business and continue providing specialized isotope and radiochemical expertise under the agreement. BWXT CEO Rex D. Geveden said the structure allows the company to remain a partner in the medical business's future growth while directing management resources toward nuclear national security and power markets. Since 2018, BWXT says it has expanded the product portfolio to include novel therapeutic isotopes.
This article was automatically created using artificial-intelligence technology and reviewed by Dow Jones Newswires editors.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments